• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

An Agreement between the DNDi Foundation and Sanofi-Aventis

Paris, France — 8 Apr 2005
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

A collaborative agreement between the DNDi Foundation and Sanofi-Aventis to develop a new, easy-to-use malaria drug at target price below one dollar
[Français]

A collaborative agreement has just been concluded between the Drugs for Neglected Diseases Initiative (DNDi) Foundation and sanofi-aventis to develop a new medicine against malaria. This is a fixed-dose combination (FDC) of artesunate and amodiaquine (AS/AQ) which is easier to use and cheaper than other combos currently available. This drug is expected to become available to patients in 2006.

                                                                                                 Download the Press Dossier

THE AGREEMENT                                                     

Because of increasing parasite resistance to animalarials, particularly chloroquine, the World Health Organisation (WHO) recommends a new treatment combining two antimalarials, one being a derivative of artemisinin. This treatment is known as “ACT” or artemisinin combination therapy.

In line with WHO experts’ recommendations, DNDi and sanofi-aventis have initiated the development of an artesunate + amodiaquine co-formulation or FDC.

In particular, the DNDi Foundation and its partners developed an original formulation combining two active ingredients in a single tablet and carried out the pharmaceutical and clinical development. The two parties then decided to join forces and signed an agreement to speed up the development of this FDC, which will become the indispensable treatment to control malaria.

In keeping with the provisions of the agreement and building on the studies conducted by DNDi, sanofi-aventis will be responsible for the development of the product, notably at industrial level, for the filing of the dossier with the regulatory authorities in the countries concerned and for WHO prequalification. The first applications should be filed by the end of 2005 or early 2006.

In agreement with DNDi, sanofi-aventis commits to sell the product at cost to the public health structures of countries affected, to international organisations and NGOs, thus facilitating access to the medicine for malaria sufferers.

THE PRODUCT

This combination is one of the first line treatments recommended by WHO and it has already been adopted by various African countries and Indonesia.

Easier to use

To improve patient compliance and to reduce the risks of resistance, the use of the drug should be as simple as possible. The new formulation is so designed that adult treatment is limited to 2 tablets per day for three days, instead of 8 tablets per day. The paediatric formulation for infants will also be simplified: one tablet a day for three days. An innovative feature of the paediatric formulation is that it can be dispersed in water, which considerably facilitates drug administration. In addition, the dosage may easily be adjusted for children and teenagers simply by giving either one or two tablets a day. Finally, the fixed-dose combination avoids the risk for patients to take one active ingredient only. Compared with the presently available co-blisters the fixed dose combination is a real step forward, because the number of tablets is reduced.

Cheaper

This new co-formulation will be less expensive than all other combinations containing artemisinin derivatives, as it combines two well-known active ingredients that are widely used in single-drug- therapy and as combinations of two separate tablets in the same blister pack. Furthermore, this new co-formulation is not covered by any patent.

Based upon WHO projections for the years to come and in line with sanofi-aventis at-cost strategy, the target price envisaged should be below one dollar for adults and 50 cents for children. This target price will only be achievable if international organisations provide adequate financial assistance to the countries concerned, thus enabling them to undertake the necessary therapeutic switch and contributing to the stabilization of raw materials markets. This price will dramatically lower the budgetary impact of the malaria treatment cost at international level.

Dr Bernard Pecoul, DNDi Foundation Executive Director, noted: “One of the key goals of the DNDi’s development strategy was to create a drug that is simple to use, at a cost below a dollar. This objective can now be met thanks to the determination of sanofi-aventis to bring this drug into the public sector at cost price”.

Jean-François Dehecq, Chairman and CEO of sanofi-aventis, said:“This highly innovative partnership between DNDi and sanofi-aventis will ensure that this new product is rapidly made available to the poorest among the poor and that it is tailored to their needs”.

 

Malaria in figures

WHO has designated Malaria, as well as HIV/AIDS and TB, as one of the major public health challenges undermining development in the poorest countries in the world.

– Malaria kills between one and two million people every year, and affects some 500 million.

– A child dies of malaria every 30 seconds in Africa.

– An estimated 40% of the world population, mostly living in the world poorest countries, is at risk of malaria

– Malaria is the leading cause of death among the under-five children in sub-Saharan Africa.

To date, over twelve national protocols in Africa and Indonesia have recommended combining artesunate and amodiaquine in a first-line treatment. This drug combination can, however, only be used in endemic zones and regions where the resistance rate for amodiaquine is below 25%.

It is estimated that dozens of millions of people could benefit from this treatment each year.

DNDi: This is the first drug developed by DNDi since its inception in 2003. DNDi intends to re-launch the research and development of new drugs against neglected diseases (trypanosomiasis, leishmaniasis, Chagas disease etc).  It’s FACT antimalaria programme – Fixed-Dose Artesunate Combination Therapy – received financial support from Médecins Sans Frontières, WHO/Tropical Diseases Research and the European Union International Cooperation programme (INCO/DEV). The success of the project fulfils DNDi’ s ambition to bring together the skills and know-how of various scientific, academic, public and private partners in the North and in the South. This success was made possible thanks to the participation of the WHO/TDR programme, TropiVal, Université de Bordeaux 2, Sains University in Malaysia, the University of Oxford, and Burkina Faso’s National Malaria Research and Training Centre.

Sanofi-Aventis: Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. The sanofi-aventis Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Through its Impact Malaria programme, Sanofi-Aventis reiterates its historic involvement in the fight against malaria, through its Impact Malaria programme and its medicines, with the derivatives of quinine and chloroquine, then with the first derivative of arteminisin, Arsumax,  being made available in Africa in 1996 and which received WHO prequalification, and with the marketing of Arsucam co-blister artenusate+amodiaquine (separate tablets put together in the same package).

The Impact Malaria programme was created in 2001 as the sanofi-aventis contribution to the fight against malaria . The four major axes are:

–       1/ to try and discover new antimalarial drugs

–  2/ to develop new combinations or formulations from existing drugs, particularly ACT’s

–   3/ to inform, educate and communicate about malaria, to reach out to  remote healthcare facilities, communities and families

–   4/ to distribute antimalarial drugs which are vital to the poorest populations, at special “no profit-no loss” cost.

These actions are carried out with public and private healthcare organisations and the health authorities in most of the countries concerned, notably through national malaria control programmes in liaison with the WHO, Roll Back Malaria Partnership and leading international institutions.    

FORWARD LOOKING STATEMENTS 

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance.  Forward-looking statements are generally identified by the words “expect,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions.  Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by Sanofi-aventis and Aventis, including those listed under “Forward-Looking Statements” and “Risk Factors” in sanofi-aventis’s annual report on Form 20-F for the year ended December 31, 2003 and those listed under “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors” in Aventis’s annual report on Form 20-F for the year ended December 31, 2003.  Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

 

Contact

Robert Sebbag, sanofi-aventis : (tel) +33 1 53 77 47 80 ; (mobile) +33 6 08 17 21 83

Jean-Francois Alesandrini, DNDi: (mobil) +41 79 596 5066

Samantha Bolton, DNDi : (tel) +41 22 906 9230 ; (mobile) +41 79 239 2366

Partnership Malaria

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo